Targeting Pre-mRNA Processing in Cancer

T. R. Webb; S. Stamm

doi:10.1016/B978-0-12-409547-2.12398-4

Targeting Pre-mRNA Processing in Cancer

T. R. Webb, S. Stamm

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

This article focuses on the development of small molecule agents that target the spliceosome as a new class of cancer therapeutics. The spliceosome is a unique macromolecular machine that has thousands of pre-mRNA substrates and potentially millions of spliced, and alternately spliced, mature mRNA products. The spliceosome and pre-mRNA splicing are now recognized to play an important role in driving oncogenesis. In parallel to this discovery, novel natural products, synthetic natural product analogs, and other small molecules have been identified that target the spliceosome and show antitumor activity. The first steps in the development of medicinal chemistry in this field are discussed.

Original language	English
Title of host publication	Cancer, Immunology and Inflammation, and Infectious Disease
Pages	341-356
Number of pages	16
Volume	5-8
ISBN (Electronic)	9780128032008
DOIs	https://doi.org/10.1016/B978-0-12-409547-2.12398-4
State	Published - Jun 3 2017

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Ltd. All rights reserved.

Keywords

Exon
Pre-mRNA
RNP
Spliceosome
Splicing

ASJC Scopus subject areas

General Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-409547-2.12398-4

Cite this

@inbook{ff99f20cffa442c5bc7896b76da47176,

title = "Targeting Pre-mRNA Processing in Cancer",

abstract = "This article focuses on the development of small molecule agents that target the spliceosome as a new class of cancer therapeutics. The spliceosome is a unique macromolecular machine that has thousands of pre-mRNA substrates and potentially millions of spliced, and alternately spliced, mature mRNA products. The spliceosome and pre-mRNA splicing are now recognized to play an important role in driving oncogenesis. In parallel to this discovery, novel natural products, synthetic natural product analogs, and other small molecules have been identified that target the spliceosome and show antitumor activity. The first steps in the development of medicinal chemistry in this field are discussed.",

keywords = "Exon, Pre-mRNA, RNP, Spliceosome, Splicing",

author = "Webb, {T. R.} and S. Stamm",

year = "2017",

month = jun,

day = "3",

doi = "10.1016/B978-0-12-409547-2.12398-4",

language = "English",

isbn = "9780128032015",

volume = "5-8",

pages = "341--356",

booktitle = "Cancer, Immunology and Inflammation, and Infectious Disease",

}

TY - CHAP

T1 - Targeting Pre-mRNA Processing in Cancer

AU - Webb, T. R.

AU - Stamm, S.

PY - 2017/6/3

Y1 - 2017/6/3

N2 - This article focuses on the development of small molecule agents that target the spliceosome as a new class of cancer therapeutics. The spliceosome is a unique macromolecular machine that has thousands of pre-mRNA substrates and potentially millions of spliced, and alternately spliced, mature mRNA products. The spliceosome and pre-mRNA splicing are now recognized to play an important role in driving oncogenesis. In parallel to this discovery, novel natural products, synthetic natural product analogs, and other small molecules have been identified that target the spliceosome and show antitumor activity. The first steps in the development of medicinal chemistry in this field are discussed.

AB - This article focuses on the development of small molecule agents that target the spliceosome as a new class of cancer therapeutics. The spliceosome is a unique macromolecular machine that has thousands of pre-mRNA substrates and potentially millions of spliced, and alternately spliced, mature mRNA products. The spliceosome and pre-mRNA splicing are now recognized to play an important role in driving oncogenesis. In parallel to this discovery, novel natural products, synthetic natural product analogs, and other small molecules have been identified that target the spliceosome and show antitumor activity. The first steps in the development of medicinal chemistry in this field are discussed.

KW - Exon

KW - Pre-mRNA

KW - RNP

KW - Spliceosome

KW - Splicing

UR - http://www.scopus.com/inward/record.url?scp=85046141115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046141115&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-409547-2.12398-4

DO - 10.1016/B978-0-12-409547-2.12398-4

M3 - Chapter

AN - SCOPUS:85046141115

SN - 9780128032015

VL - 5-8

SP - 341

EP - 356

BT - Cancer, Immunology and Inflammation, and Infectious Disease

ER -

Targeting Pre-mRNA Processing in Cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this